Moreover, a phase I trial with the AAV9-mini-dystrophin vector is in progress in 4-12-year-old DMD patients for the verification of safety, tolerability, dystrophin expression and distribution, and muscle strength [247]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.